WF6 Stock Overview
Operates as a clinical stage drug development company in Canada, Australia, and New Zealand.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MindBio Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.02 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.0074 |
| Beta | 0 |
| 11 Month Change | 160.53% |
| 3 Month Change | 90.38% |
| 1 Year Change | 8.79% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| WF6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -1.8% |
| 1Y | 8.8% | -12.8% | 13.6% |
Return vs Industry: WF6 exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: WF6 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| WF6 volatility | |
|---|---|
| WF6 Average Weekly Movement | 92.8% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WF6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WF6's weekly volatility has increased from 65% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Justin Hanka | www.mindbiotherapeutics.com |
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. Its LSD-microdosing is currently under Phase 2 clinical trials for the treatment of major depressive disorder and microdosing of LSD in late-stage cancer patients.
MindBio Therapeutics Corp. Fundamentals Summary
| WF6 fundamental statistics | |
|---|---|
| Market cap | €3.12m |
| Earnings (TTM) | -€251.56k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.4x
P/E RatioIs WF6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WF6 income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$415.64k |
| Earnings | -AU$415.64k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -87.4% |
How did WF6 perform over the long term?
See historical performance and comparison